Patients with chronic kidney disease (CKD) are
|
|
- Nicholas Harmon
- 5 years ago
- Views:
Transcription
1 CLINICAL INTERVENTIONS TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH KIDNEY DISEASE Jeffrey S. Berns, MD* ABSTRACT Although the specific mechanisms by which chronic kidney disease (CKD) and cardiovascular disease (CVD) compound the effects of one another have not been identified, there are practical therapies physicians can use to reduce the risk of mortality associated with these diseases. Clinical trial evidence suggests that treating modifiable risk factors can reduce the risks of CKD progression and of cardiovascular events. As patients progress through the stages of kidney disease, mortality risk dramatically increases, and the majority of these deaths are the result of cardiovascular events. The modifiable risk factors for the progression of CKD and of CVD have significant overlap. Among these risk factors, anemia has been shown to compound the problems of CKD and to confer significant additional cardiovascular risk. Studies suggest that correcting anemia in patients with CKD may provide cardiovascular benefit, such as improvements in detrimental cardiac remodeling. Correcting anemia in the early stages of kidney disease may provide additional cardiovascular protection by slowing the progression of kidney disease. Currently, there are 2 available pharmacologic treatments for anemia: recombinant human erythropoietin and darbepoetin alfa. Both treatments are safe and effective, and the long half-life of darbepoetin alfa potentially allows for less frequent dosing. Anemia is one of the more manageable risk factors in patients with CKD. Managing risk factors such as anemia may provide significant cardiovascular benefit for this high-risk population. (Adv Stud Med. 25;5(7A):S72-S725) : *Associate Professor of Medicine, Renal, Electrolyte, and Hypertension Division, University of Pennsylvania, Philadelphia, Pennsylvania. Address correspondence to: Jeffrey S. Berns, MD, Renal, Electrolyte, and Hypertension Division, Presbyterian Medical Center, 51 N. 39th St, 24 Medical Office Bldg, Philadelphia, PA bernsj@uphs.upenn.edu. Patients with chronic kidney disease (CKD) are at high risk for developing cardiovascular disease (CVD). Observational studies show a strong link between the diseases, but the specific mechanisms by which they compound one another s detrimental effects have yet to be identified. Nevertheless, there are practical therapies that physicians can use to limit the risk of mortality from these diseases. For instance, risk factors, such as hypertension, dyslipidemia, proteinuria, and anemia, can be successfully treated. The National Kidney Foundation has issued the Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines for Chronic Kidney Disease, 1 which recommend that all patients with CKD should be considered in the highest risk category for developing CVD, regardless of the absence of traditional risk factors. The K/DOQI guidelines provide therapeutic targets for the risk factors associated with CKD, and clinical trial evidence suggests that treating modifiable risk factors can reduce the risk of CKD progression and the risk of cardiovascular events. The American Heart Association and the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII) also recognize the contribution of CKD as an important cardiovascular disease risk factor. 2,3 MANAGING RISK FACTORS HYPERTENSION The K/DOQI guidelines recommend a target blood pressure for cardiovascular risk reduction of below 13/8 mm Hg, acknowledging that a multidrug regimen will be needed in most patients to lower their blood pressure to this level. Diuretics should be part of the antihypertensive regimen in most patients. Angiotensinconverting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are recommended for patients with proteinuria or diabetes mellitus. 4 S72 Vol. 5 (7A) July 25
2 LIPIDS Low-density lipoprotein (LDL) cholesterol levels should be maintained below 1 mg/dl according to the K/DOQI guidelines, which for the most part follow the recommendations of the National Cholesterol Education Program Adult Treatment Panel III (ATP III) guidelines. 5 Although diet and lifestyle modification may be beneficial for some patients, LDL level reductions achieved are usually insufficient to obtain the desired LDL target. In most patients who do not achieve LDL levels below 1 mg/dl with lifestyle modification alone, statins are recommended as first-line therapy. In patients with advanced kidney disease, the initial doses of statins other than atorvastatin and pravastatin need to be reduced by 5%. Patients being treated with cyclosporine (and probably tacrolimus) also need to be treated with reduced doses of statins because cyclosporine increases blood levels of these drugs. Bile acid sequestrants are recommended as secondline therapy for patients who cannot tolerate statins and who do not have significant hypertriglyceridemia. Niacin is recommended for patients who cannot be treated with bile acid sequestrants. For patients with elevated triglycerides, therapy should include fibrates or niacin, with the caveat that fibrates and statins should not be used in combination because of musculoskeletal risk. Prospective studies of statins in patients with CKD are few. However, a recent post hoc analysis of the pooled results from 3 pravastatin trials 6 showed that the presence of moderate CKD, defined as a glomerular filtration rate (GFR) of 3 to 6 ml/min/1.73 m 2, was associated with a 26% increase in the risk of myocardial infarction (MI), coronary intervention, or coronary death compared with those patients who had normal kidney function. The use of pravastatin in patients with moderate CKD was associated with a 23% reduction in the risk of MI, coronary intervention, or coronary death and a 14% reduction in all-cause mortality. These data suggest that statins offer some degree of cardiovascular protection for patients with CKD. Prospective studies of the effect of statins on CKD progression are limited. A 1-year study of atorvastatin showed that patients with CKD who received the statin in combination with ACE inhibitors or ARBs and other antihypertensive drugs had a greater reduction in urinary protein excretion. 7 Likewise, the patients with CKD who received the statin showed a much smaller decrease in creatinine clearance, a signal of slower decline in kidney function. Ongoing studies will hopefully provide more information about this important topic in the near future. HOMOCYSTEINE Hyperhomocysteinemia has been associated with a variety of types of CVD, such as coronary artery disease, peripheral vascular disease, and stroke. Homocysteine levels are also inversely related to GFR. Consequently, most dialysis patients have elevated homocysteine levels. In the general population, elevated homocysteine levels can usually be managed easily with folic acid supplementation. However, in patients with CKD, elevated homocysteine levels can rarely be normalized, even with high-dose (5-2 mg) folic acid supplements. Although elevated homocysteine levels are associated with poorer cardiovascular outcomes, studies have yet to show that correcting hyperhomocysteinemia in patients with CKD confers a reduction in cardiovascular risk. CALCIUM-PHOSPHORUS METABOLISM The Dialysis Outcomes and Practice Patterns study analyzed the relationship between calcium levels, phosphorous levels, and the calcium-phosphorous product and mortality in dialysis patients. Both cardiovascular and all-cause mortality were associated with higher calcium and phosphorous levels and a higher calcium-phosphorus product. 8 There was a significantly increased mortality risk above a calciumphosphorus product of approximately 65 mg 2 /dl 2, a finding that is consistent with earlier studies. 9 Although data in patients with CKD who are not undergoing dialysis are limited, the K/DOQI guidelines recommend maintaining total serum calcium between 8.4 and 9.5 mg/dl and limiting calcium intake to 2 g/day. 1 This daily limit on recommended intake could be easily exceeded, particularly in dialysis patients, through the normal dietary intake of calcium with the addition of calcium from phosphate binders. The guidelines also recommend that serum phosphorous levels be maintained between 2.7 and 4.6 mg/dl in CKD stages 3 to 4 and between 3.5 and 5.5 mg/dl in stage 5 CKD by using dietary phosphorous restriction and judicious use of phosphate binders when needed. The K/DOQI recommendations also indicate that the calcium-phosphorous product should be maintained at below 55 mg 2 /dl 2 through control of the serum phosphorous level. Advanced Studies in Medicine S721
3 Although unproved as a predictor of cardiovascular events in patients with CKD, coronary calcification is increasingly recognized as a common finding in these patients and may at least in part be the result of inadequately controlled calcium and phosphorous levels or excessive total calcium intake. The Dallas Heart Study recently analyzed coronary artery calcification scores by electron-beam computed tomography (EBCT) scanning in a variety of patients. 11 Figure 1 shows that patients in progressively more advanced stages of CKD had progressively higher coronary artery calcification scores. This was particularly dramatic in subjects with CKD and diabetes mellitus, in whom coronary artery calcification scores were markedly elevated compared with patients who did not have diabetes mellitus. Although a recent study did report an association between coronary artery calcification and the extent of angiographically demonstrated coronary atherosclerosis in patients with CKD, 12 it remains to be proven whether coronary artery calcification is associated with greater risk of cardiovascular events or that maintaining tight calcium-phosphorus control reduces cardiovascular risk in patients with CKD. TREATING THE CKD-CVD ENTITY Patients with CKD are more likely to die than to progress to end-stage renal disease. Figure 2 shows the 5-year follow-up results from a study of patients with CKD. 13 For patients at each progressively higher stage of kidney disease, the risk of death was dramatically higher. Patients in this study who had stage 4 kidney disease had a mortality rate over 5 years exceeding 45%. These data suggest that preventing the progression of CKD may confer cardiovascular benefit. Many of the risk factors for progression of CKD are also risk factors for CVD, and many of these, such as hypertension, albuminuria/proteinuria, dyslipidemia, smoking, and anemia, are modifiable. Perhaps then, physicians should be thinking about treatments to slow the progression of CKD in terms of the potential of these treatments to also slow the progression of CVD. As an example, data from the Losartan Intervention for Endpoint Reduction (LIFE) trial showed a strong correlation between the risk of cardiovascular events and the severity of microalbuminuria (Figure 3). 14 The severity of microalbuminuria can be modified through blood pressure control and the use of ACE inhibitors and ARBs. Reducing microalbuminuria in this way has been associated with slowing of the progression of CKD and may limit the associated cardiovascular risk. Figure 1. Coronary Artery Calcification Progresses with Kidney Disease No CKD CKD Stage 1-2 CKD Stage 3-5 DM CKD Stage 1-2 DM CKD Stage 3-5 % 5% 1% CAC 1 CAC = 11-1 CAC = 11-4 CAC >4 CKD = chronic kidney disease; DM = diabetes mellitus; CAC = coronary artery calcification. Reprinted with permission from Kramer et al. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol. 25;16(2): Figure 2. Mortality is More Common than Progression to ESRD Patients (%) ESRD = end-stage renal disease. Data from Keith et al RRT Died Stage 1 Stage 2 Stage 3 Stage 4 Event free Disenrolled S722 Vol. 5 (7A) July 25
4 Anemia has also been identified as a significant mortality risk factor, conferring about the same mortality risk in patients with CKD as the deadly combination of diabetes mellitus and congestive heart failure (CHF). 15 Anemia in patients with CKD has been clearly associated with increased risk of stroke, cardiovascular events, CHF, hospitalization, and mortality. Figure 4 shows that for patients with decompensated CHF, the number of days spent in the hospital and inhospital mortality were higher among patients with hemoglobin (Hb) levels below 11.4 g/dl compared with those with higher Hb levels. 16 In the same study, mortality at 6 days and the combined end point of rehospitalization or death (6 days) were also higher in patients with lower Hb levels. Anemia is a readily modifiable CVD risk factor that can be safely treated. Evidence suggests that anemia correction in patients with CKD may confer important cardiovascular benefits. A few small studies have suggested that treating moderately severe anemia results in reductions in left ventricular hypertrophy and left ventricular dilatation One study of anemia correction with erythropoietin showed that raising baseline Hb from 8 g/dl to 1 g/dl was associated with a marked reduction in left ventricular mass index (LVMI) and end-diastolic volume over a 12-month period. Upon cessation of erythropoietin treatment, the patients became anemic again, and their improvements in LVMI and end-diastolic volume regressed (Figure 5). 2 Another study in anemic patients with left ventricular hypertrophy examined the effects of raising Hb above 1 g/dl to 13.5 g/dl with erythropoietin treatment. 21 This study did not show that achieving this higher level of Hb conferred additional cardiac benefits. Patients did, however, have improved quality of life. A study of patients with severe, resistant CHF who underwent erythropoietin and iron treatment to raise their mean Hb from about 1.5 g/dl to 13 g/dl showed a statistically significant reduction in New York Heart Association functional class and scores on an index of symptoms such as fatigue and shortness of breath, and improved left ventricular ejection fraction. 22 Hospitalizations were also significantly reduced, by more than 95%. Treatment of anemia had no adverse effects on GFR or blood pressure. In addition to beneficial cardiac effects, treatment of anemia also appears to have beneficial effects in terms of slowing progression of CKD. A study exam- Figure 3. Cardiovascular Risk Increased with the Severity of Microalbuminuria Relative Risk Composite End point CV Mortality All-Cause Mortality CV = cardiovascular; MI = myocardial infarction. Data from Wachtell et al. 14 Stroke Figure 4. Length of Hospitalization and In-hospital Mortality Increased with Anemia Severity Hospital Days (n) In-hospital Mortality, % Data from Felker et al. 16 P = >13.9 Hemoglobin Level P = >13.9 Hemoglobin Level MI Advanced Studies in Medicine S723
5 ining the effects of early versus delayed erythropoietin treatment showed that patients with CKD who were treated earlier, with mild-to-moderate stages of anemia, had lower mortality and were less likely to require renal replacement therapy than patients whose treatment was delayed until they were more severely anemic. 23 These studies suggest that correcting severe Figure 5. Recurrence of LVH Following Cessation of Erythropoietin Therapy LVMI (g/m 2 ) Baseline (Hgb 7.9 g/dl) 12 months + EPO (Hgb 1 g/dl) 12 months EPO (Hgb 7.9 g/dl) EDV (ml) LVH = left ventricular hypertrophy; LVMI = left ventricular mass index; EDV = end-diastolic volume; Hgb = hemoglobin; EPO = erythropoietin. Data from Sikole et al. 2 Figure 6. Anemia Can Be Successfully Treated in CKD Patients Hemoglobin Level (g/dl) E 37 D CKD = chronic kidney disease. Data from Locatelli et al Study Week Erythropoietin Darbepoetin anemia may have a positive effect on measurable cardiovascular outcomes, such as left ventricular mass index. They also suggest that correcting anemia in the early stages of kidney disease may slow kidney disease progression, thereby reducing mortality risk. There are 2 pharmacologic therapies approved in the United States for the treatment of anemia. Recombinant human erythropoietin has the same amino acid backbone as the native hormone. Darbepoetin alfa, a modified form of recombinant human erythropoietin, has a slightly different amino acid structure from the native hormone and a higher carbohydrate content than recombinant erythropoietin. Darbepoetin alfa offers the advantage of a longer serum half-life than recombinant human erythropoietin, allowing less frequent dosing. A comparative study of once-weekly darbepoetin and twice-weekly recombinant erythropoietin showed no difference in efficacy. Figure 6 shows that both treatment groups achieved the target Hb range of 11 g/dl to 13 g/dl within 6 to 7 weeks. 24 The K/DOQI guidelines recommend a target Hb level of 11 g/dl to 12 g/dl. 25 This target is easily achievable with current therapies. Successful anemia treatment requires 2 agents at most: iron and either recombinant erythropoietin or darbepoetin alfa. Hypertension, by comparison, typically requires 2 to 3 agents or more to achieve adequate control. The efficacy of anemia treatment, coupled with the potential for infrequent dosing with darbepoetin alfa, make anemia one of the more easily treatable risk factors in patients with CKD. As stated earlier, all patients with CKD should be considered in the highest risk category for developing CVD. The appropriate management of risk factors, such as hypertension, proteinuria, dyslipidemia, calcium-phosphorous metabolism, and anemia, has the potential to reduce cardiovascular risk in patients with CKD. REFERENCES 1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 22;39(2, suppl 1):S1-S Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 23;18(17): S724 Vol. 5 (7A) July 25
6 3. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 23;289(19): Kidney Disease Outcomes Quality Initiative. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 24;43(5, suppl 1):S1-S Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 21;285(19): Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 24;11(12): Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 23;41(3): Erratum in: Am J Kidney Dis. 24;43(1): Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 25;67(3): Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4): National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 23;42(4, suppl 3):S1-S Kramer H, Toto R, Peshock R, Cooper R, Victor R. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol. 25;16(2): Haydar AA, Hujairi NM, Covic AA, Pereira D, Rubens M, Goldsmith DJ. Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography. Nephrol Dial Transplant. 24;19(9): Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 24;164(6): Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 23;139(11): Collins A. The hemoglobin link to adverse outcomes. Adv Stud Med. 23;3(3C):S194-S Felker GM, Gattis WA, Leimberger JD, et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol. 23;92(5): Wizemann V, Schafer R, Kramer W. Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy. Nephron. 1993;64(2): Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis. 1997;29(4): Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis. 2;35(2): Sikole A, Polenakovic M, Spiroska V, Polenakovic B, Klinkmann H, Scigalla P. Recurrence of left ventricular hypertrophy following cessation of erythropoietin therapy. Artif Organs. 22;26(2): Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2;58(3): Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant. 23;18(1): Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 24;66(2): Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int. 21;6(2): IV.NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2. Am J Kidney Dis. 21;37(1, suppl 1):S182-S238. Erratum in: Am J Kidney Dis. 21;38(2):442. Advanced Studies in Medicine S725
7 NOTES S726 Vol. 5 (7A) July 25
Published trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationLessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
More informationCKD and CVD. Jamal Salameh, MD, FACP, FASN First Coast Nephrology
CKD and CVD Jamal Salameh, MD, FACP, FASN First Coast Nephrology An Epidemic of Kidney Disease Prevalence CKD stages 1-4 10% 1988-94 13% 1999-2004 Coresh, JAMA 298:2038, 2007 Stage 5: GFR
More informationBecause of important technologic advances achieved over
Anemia and Heart Failure in Chronic Kidney Disease Francesco Locatelli, Pietro Pozzoni, and Lucia Del Vecchio Cardiovascular disease is mainly responsible for the poor long-term survival observed in chronic
More informationCHRONIC RENAL FAILURE: WHAT THE PRIMARY CARE CAN OFFER. The annual conference of the Lebanese Society of Family Medicine October 2017 Dr Hiba AZAR
CHRONIC RENAL FAILURE: WHAT THE PRIMARY CARE CAN OFFER The annual conference of the Lebanese Society of Family Medicine October 2017 Dr Hiba AZAR OUTLINE: A journey through CKD Screening for CKD: The why,
More informationAnemia Update. Target Hb TREAT study Functional iron deficiency - Hepcidin Biosimilar epoetins
Anemia Update Peter Bárány Department of Renal Medicine/ Karolinska University Hospital and Division of Renal Medicine Department of Clinical Science, Intervention and Technology Karolinska Institutet,
More informationCardiovascular Mortality: General Population vs ESRD Dialysis Patients
Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP
More informationA rationale for an individualized haemoglobin target
Nephrol Dial Transplant (2002) 17 [Suppl 6 ]: 2 7 A rationale for an individualized haemoglobin target Norman Muirhead University of Western Ontario, London, Ontario, Canada Abstract Despite the use of
More informationPrevalence of anemia and cardiovascular diseases in chronic kidney disease patients: a single tertiary care centre study
International Journal of Advances in Medicine Sathyan S et al. Int J Adv Med. 2017 Feb;4(1):247-251 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20170120
More informationFigure 1 LVH: Allowed Cost by Claim Volume (Data generated from a Populytics analysis).
Chronic Kidney Disease (CKD): The New Silent Killer Nelson Kopyt D.O. Chief of Nephrology, LVH Valley Kidney Specialists For the past several decades, the health care needs of Americans have shifted from
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationThe cardiologist s interest in renal function
ASSESSING CARDIOVASCULAR RISK IN PATIENTS WITH CHRONIC KIDNEY DISEASE Jeffrey Brinker, MD* ABSTRACT The manifestations of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD) are
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationCKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College
CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)
More informationhyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER
Management of hyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER Background on Dyslipidemia in CKD In advanced chronic kidney disease (CKD),
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationApplying clinical guidelines treating and managing CKD
Applying clinical guidelines treating and managing CKD Develop patient treatment plan according to level of severity. Source: Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012
More informationLab Values Explained. working at full strength. Other possible causes of an elevated BUN include dehydration and heart failure.
Patient Education Lab Values Explained Common Tests to Help Diagnose Kidney Disease Lab work, urine samples and other tests may be given as you undergo diagnosis and treatment for renal failure. The test
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationJOSHUA K. KAYIMA INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY
INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY JOSHUA K. KAYIMA ASSOCIATE PROFESSOR DEPT. OF CLINICAL MEDICINE AND THERAPEUTICS UNIVERSITY OF NAIROBI Introduction According to
More informationPrevalence of cardiovascular damage in early renal disease
Nephrol Dial Transplant 2001) 16 wsuppl 2x: 7±11 Prevalence of cardiovascular damage in early renal disease Adeera Levin University of British Columbia, Renal Insuf ciency Clinic, Vancouver, Canada Abstract
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More information(renoprotective (end-stage renal disease, ESRD) therapies) (JAMA)
[1], 1., 2. 3. (renoprotective (end-stage renal disease, ESRD) therapies) (JAMA) (multiple risk (renal replacement therapy, RRT) factors intervention treatment MRFIT) [2] ( 1) % (ESRD) ( ) ( 1) 2001 (120
More informationInflammation in Renal Disease
Inflammation in Renal Disease Donald G. Vidt, MD Inflammation is a component of the major modifiable risk factors in renal disease. Elevated high-sensitivity C-reactive protein (hs-crp) levels have been
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More informationHTA ET DIALYSE DR ALAIN GUERIN
HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationThe impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure
Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationNATIONAL QUALITY FORUM Renal EM Submitted Measures
NATIONAL QUALITY FORUM Renal EM Submitted Measures Measure ID/ Title Measure Description Measure Steward Topic Area #1662 Percentage of patients aged 18 years and older with a diagnosis of CKD ACE/ARB
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Educational Objectives Outline Demographics Propose Strategies to slow progression and improve outcomes Plan for treatment of CKD Chronic Kidney Disease
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationLong-Term Care Updates
Long-Term Care Updates January 2016 By Yunuo (Enora) Wu, PharmD Chronic kidney disease (CKD) is defined as kidney damage (including structural or functional abnormalities) or glomerular filtration rate
More informationAddressing Chronic Kidney Disease in People with Multiple Chronic Conditions
Addressing Chronic Kidney Disease in People with Multiple Chronic Conditions Andrew S Narva, MD Na/onal Kidney Disease Educa/on Program U.S. Department of Health and Human Services National Institute of
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationManagement of Early Kidney Disease: What to do Before Referring to the Nephrologist
Management of Early Kidney Disease: What to do Before Referring to the Nephrologist Andrew S. Narva, MD, NIDDK Saturday, February 18, 2017 8:45 a.m. 9:30 a.m. Although evidence-based guidelines for managing
More informationRisk Factors in the Progression of Chronic Kidney Disease
Risk Factors in the Progression of Chronic Kidney Disease a report by Rainer Düsing Professor, Faculty of Medicine, University of Bonn DOI:10.17925/EE.2006.00.02.1e Chronic kidney disease (CKD) is a complex,
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationThe hypertensive kidney and its Management
The hypertensive kidney and its Management Dr H0 Chung Ping Hypertension Management Seminar 20061124 Hypertensive kidney Kidney damage asymptomatic till late stage Viscous cycle to augment renal damage
More informationChronic Kidney Disease as cardiovascular risk predictor Evidence based clinical management. Fabio Mazza
Chronic Kidney Disease as cardiovascular risk predictor Evidence based clinical management Fabio Mazza CKD (Chronic Kidney Disease) is an ever-increasing clinical condition marked by a progressive reduction
More informationStages of chronic kidney disease
For mass reproduction, content licensing and permissions contact Dowden Health Media. Jonathan J. Taliercio, DO Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio talierj@ccf.org
More informationTREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009
TREAT THE KIDNEY TO SAVE THE HEART Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 1 ESRD Prevalent Rates in 1996 per million population December
More informationThe Seventh Report of the Joint National Commission
The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study Mark J. Sarnak, MD; Tom Greene, PhD; Xuelei Wang,
More informationOffice Management of Reduced GFR Practical advice for the management of CKD
Office Management of Reduced GFR Practical advice for the management of CKD CKD Online Education CME for Primary Care April 27, 2016 Monica Beaulieu, MD FRCPC MHA CHAIR PROVINCIAL KIDNEY CARE COMMITTEE
More informationRETARDING PROGRESSION OF CHRONIC KIDNEY DISEASE (CKD)
13 : 6 RETARDING PROGRESSION OF CHRONIC KIDNEY DISEASE (CKD) Abstract: Chronic Kidney Disease (CKD) is common, harmful and treatable. It is worldwide public health problem, with several adverse outcomes;
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationElevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC
Elevation of Serum Creatinine: When to Screen, When to Refer Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC Presented at the University of Calgary s CME and Professional Development 2006-2007
More informationEffective Health Care Program
Comparative Effectiveness Review Number 37 Effective Health Care Program Chronic Kidney Disease Stages 1 3: Screening, Monitoring, and Treatment Executive Summary Objectives This systematic review evaluates
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationComplications of Chronic Kidney Disease: Anemia, Mineral Metabolism, and Cardiovascular Disease
Med Clin N Am 89 (2005) 549 561 Complications of Chronic Kidney Disease: Anemia, Mineral Metabolism, and Cardiovascular Disease Shona Pendse, MD, Ajay K. Singh, MB, MRCP(UK)* Renal Division, Brigham and
More informationIrish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012
Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012 Susan McKenna Renal Clinical Nurse Specialist Cavan General Hospital Renal patient population ACUTE RENAL FAILURE
More informationSAMPLE. Chronic Kidney Disease, Evidence-Based Practice, and the Nutrition Care Process. Chapter 1
Chapter 1 Chronic Kidney Disease, Evidence-Based Practice, and the Nutrition Care Process This guide follows the steps of the Nutrition Care Process (NCP) nutrition assessment, nutrition diagnosis, nutrition
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence
More informationAssessment of High-Sensitive Cardiac Troponin I in Coronary Artery Disease Patients Undergoing Regular Hemodialysis
The Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (4), Page 6571-6576 Assessment of High-Sensitive Cardiac Troponin I in Coronary Artery Disease Patients Undergoing Regular Hemodialysis
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More information신장환자의혈압조절 나기영. Factors involved in the regulation of blood pressure
신장환자의혈압조절 K/DOQI Clinical practice guidelines on Hypertension and Antihypertensive agents in CKD 나기영 Factors involved in the regulation of blood pressure Renal function curve MAP (mmhg) Central role of
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationAssessment of Risk Factors for Cardiovascular Complications in Patients with Chronic Kidney Disease (CKD) Stage III- V before Dialysis
University Heart Journal Vol. 9, No. 1, January 2013 Assessment of Risk Factors for Cardiovascular Complications in Patients with Chronic Kidney Disease (CKD) Stage III- V before Dialysis KHAN MK 1, RASHID
More informationScreening and early recognition of CKD. John Ngigi (FISN) Kidney specialist
Screening and early recognition of CKD John Ngigi (FISN) Kidney specialist screening Why? Who? When? How? Primary diagnosis for patients who start dialysis Other 10% Glomerulonephritis 13% No. of dialysis
More informationErythropoietin Friend or Foe in Chronic Kidney Disease Anemia: An Analysis of Randomized Controlled Trials, Observational Studies and Meta-analyses
BJMP 2009:2(3) 12-20 Review Article Erythropoietin Friend or Foe in Chronic Kidney Disease Anemia: An Analysis of Randomized Controlled Trials, Observational Studies and Meta-analyses analyses Amir Hayat
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Protein Restriction to prevent the progression of diabetic nephropathy GUIDELINES
Protein Restriction to prevent the progression of diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. A small volume of evidence suggests
More informationIN THE LAST few decades, several important
Anemia Management for Hemodialysis Patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) Guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) Findings Francesco Locatelli, MD, Ronald
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationEvaluation of the effect of oral versus intravenous iron treatments on anemia in patients with chronic kidney diseases.
Evaluation of the effect of oral versus intravenous iron treatments on anemia in patients with chronic kidney diseases. Arif Sami Malik FICMS. Abstract Background:Correction of anemia as a result of renal
More informationKidney Disease. Chronic kidney disease (CKD) requiring dialysis. The F.P. s Role in the Management of Chronic. Stages
Focus on CME at McMaster University The F.P. s Role in the Management of Chronic Kidney Disease By David N. Churchill, MD, FRCPC, FACP Presented at McMaster University CME Half-Day in Nephrology for Family
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationDiabetes in Renal Patients. Contents. Understanding Diabetic Nephropathy
Diabetes in Renal Patients Contents Understanding Diabetic Nephropathy What effect does CKD have on a patient s diabetic control? Diabetic Drugs in CKD and Dialysis Patients Hyper and Hypoglycaemia in
More informationS150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153
S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meeting 12 th September 2017 - Sheffield Prof Sunil Bhandari Consultant
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More information